Artisan Partners Limited Partnership Invests $519,000 in DBV Technologies S.A. $DBVT

Artisan Partners Limited Partnership acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 51,920 shares of the company’s stock, valued at approximately $519,000. Artisan Partners Limited Partnership owned approximately 0.15% of DBV Technologies at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. New York State Common Retirement Fund acquired a new stake in shares of DBV Technologies in the 3rd quarter valued at about $34,000. Nan Fung Trinity HK Ltd. acquired a new position in shares of DBV Technologies during the second quarter worth about $340,000. Octagon Capital Advisors LP bought a new position in shares of DBV Technologies during the second quarter worth about $9,315,000. MPM Bioimpact LLC acquired a new stake in DBV Technologies in the 2nd quarter valued at approximately $9,649,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in DBV Technologies in the 2nd quarter valued at approximately $9,659,000. 71.74% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other DBV Technologies news, major shareholder Bpifrance Epic sold 1,292,103 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $4.19, for a total transaction of $5,413,911.57. Following the transaction, the insider owned 7,303,369 shares of the company’s stock, valued at $30,601,116.11. The trade was a 15.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last quarter, insiders have sold 3,369,627 shares of company stock valued at $15,489,908. 1.44% of the stock is currently owned by corporate insiders.

DBV Technologies Trading Down 2.5%

NASDAQ DBVT opened at $20.99 on Friday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -4.06 and a beta of -0.98. The firm’s fifty day moving average price is $20.62 and its two-hundred day moving average price is $15.69. DBV Technologies S.A. has a 1 year low of $3.82 and a 1 year high of $26.18.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research note on Wednesday, December 17th. Wall Street Zen upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Sunday, February 8th. Citizens Jmp lifted their price target on shares of DBV Technologies from $21.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday, December 17th. Guggenheim reissued a “buy” rating and set a $51.00 price target (up from $35.00) on shares of DBV Technologies in a research report on Wednesday, December 17th. Finally, HC Wainwright set a $40.00 price objective on DBV Technologies in a report on Thursday, December 18th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.25.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.